Tolerability of antipsychotic drugs: Does patient perspective deserve consideration?

Epidemiologia e Psichiatria Sociale

Volumn 17, Issue 3, 2008, Pages 182-185

  Nosè, Michela ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ANTICHOLINERGIC EFFECT; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; HUMAN; LONG TERM CARE; MEMORY DISORDER; MENTAL DISEASE; MENTAL HEALTH CARE; METABOLIC DISORDER; MONOTHERAPY; PARKINSONISM; PATIENT COMPLIANCE; PSYCHOLOGICAL RATING SCALE; PSYCHOMETRY; QUALITY OF LIFE; SCHIZOPHRENIA; SELF CONCEPT; SELF REPORT; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STIGMA; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 53849117779     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/s1121189x00001251     Document Type: Editorial

References (24)

1. Barbui C., Nosè M., Bindman J., Schene A., Becker T., Mazzi M.A., Kikkert M., Camara J., Born A. & Tansella M. (2005). Sex differences in the subjective tolerability of antipsychotic drugs. Journal of Clinical Psychopharmacology 25, 521-526.
2. Barbui C., Cipriani A., Malvini L., Nosè M., Accordini S., Pontarollo F., Veronese A., Tansella M & CHAT investigators (2006). Trasformare la pratica clinica in ricerca. Un invito a partecipare allo studio CHAT. Rivista di Psichiatria 41, 326-330.
3. Barnes T.R.E. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry 154, 672-676.
4. Castle D., Morgan V. & Jablensky A. (2002), Antipsychotic use in Australia: the patients' perspective. Australian & New Zealand Journal of Psychiatry 36(5), 633-641.
5. Day J.C., Wood G., Dewey M. & Bentall R.P. (1995). A self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients. British Journal of Psychiatry 166, 650-653.
6. Day J.C., Kinderman P. & Bentall R. (1998). A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatrica Scandinavica 97(1), 93-97.
7. Day J.C., Bentall R.P., Roberts C., Randall F., Rogers A., Cattell D., Healy D., Rae P. & Power C. (2005). Attitudes toward antipsychotic medication. Archives of General Psychiatry 62, 717-724.
8. Fenton W.S., Blyler C.R. & Heinssen R.K. (1997). Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophrenia Bulletin 23, 637-651.
9. Finn S.E., Bailey J.M., Schultz R.T. & Faber R. (1990). Subjective utility ratings of neuroleptic in treating schizophrenia. Psychological Medicine 20, 843-848.
10. Gray R., Robson D. & Bressington D. (2002). Medication management for people with a diagnosis of schizophrenia. Nursing Time 98, 38-40.
11. Hamer S. & Haddad P. (2007). Adverse effects of antipsychotics as outcome measures. British Journal of Psichiatry 191, Suppl 50, 64-70.
12. Huffman J.C., Blais M.A. & Pirl W.F. (2004). A comparison of clinician and patient concerns about antipsychotic side effects: a pilot study. Journal of Nervous and Mental Disorder 192, 328-330.
13. Inada T., Beasley C.M., Tanaka Y. & Walker D.J. (2003). Extrapyramidal symptom profiles assessed with the Drug-Induced Extrapyramidal Symptom Scale. International Clinical Psychopharmacology 18, 39-48.
14. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., Gheorghe M.D., Rybakowski J.K., Galderisi S., Libiger J., Hummer M., Dollfus S., López-Ibor J.J., Hranov L.G., Gaebel W., Peuskens J., Lindefors N., Riecher-Rössler A., Grobbee D.E. & EUFEST study group (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371, 1085-97.
15. Kampman O., Laippala P., Vaananen J., Koivisto E., Kiviniemi P., Kilkku N. & Lehtinen K. (2002). Indicators of medication compliance in first episode psychosis. Psychiatry Research 110, 39-48.
16. Lambert T.J.R., Cock N., Alcock J., Kelly D.L. & Conley R.R. (2003). Measurement of antipsychotic-induced side effects: support for the validity of self-report (LUNSERS) versus structured interview (UKU) approach to measurement. Human Psychopharmacoly-Clinical and Experimental 18, 405-411.
17. Lieberman J.A., Stroup T.S., McEvoy J.P., Seartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. & Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353, 1209-1223.
18. Lingjaerde O., Ahlfors V.G. & Dech P. (1987). The UKU side effect rating scale for psychotropic drugs and a cross sectional study of side effects in neuroleptic treated patients. Acta Psychiatrica Scandinavica, Supplementum No. 334, 76.
19. McGorry P.D. &, Killackey E.J. (2002). Early intervention in psychosis: a new evidence based paradigm. Epidemiologia e Psichiatria Sociale 11, 237-247.
20. Morrison P., Gaskill D., Meehan T., Lunney P., Lawrence G. & Collings P. (2000). The use of the Liverpool University Neuroleptic Side-Effect Rating Scale (LUNSERS) in clinical practice. Australian & New Zealand Journal of Mental Health Nursing 9, 166-176.
21. Nosè M., Barbui C., Gray R. & Tansella M. (2003a). Clinical interventions for treatment non-adherence in psychosis: meta-analysis. British Journal of Psychiatry 183, 197-206.
22. Nosè M., Barbui C. & Tansella M. (2003b). How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychological Medicine 33, 1149-1160.
23. Simpson J.A. & Angus J.W.S (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica, Supplementum 212, 11-19.
24. Vorunganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S. & Awad A. (2000). Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43, 135-145.